Bookshelf

Review authors' judgements about each methodological quality item for each included study. Minus sign, negative score; plus sign, positive score; question mark, unclear whether item scores negatively or positively; blank space, not applicable.
a, Data from Fabbri et al.57 and Stein et al.71 b, Ono et al.63 recruited two separate cohorts for validation and derivation. The derivation cohort was treated differently for the ICI outcome: the reference standard was not adequate, it was unclear whether partial verification bias was avoided and differential verification bias was not avoided. c, Smits et al.68–70

Algorithmic approach for hematological manifestations of rheumatoid arthritis (RA). Classified by the affected component of the blood (platelets, HB, or WBC), in this approach; the authors suggest to broaden the differential diagnosis and to rule out non-rheumatological causes of mentioned abnormalities, including systemic diseases, infections, and drug-induced and primary hematological diseases. The evidence to support this approach is based on cumulative literature, current guidelines, and the author’s experience (Abbreviations: RA rheumatoid arthritis, R/O rule out, HCV hepatitis C virus, HIV human immunodeficiency virus, TSH thyroid stimulating hormone, PT prothrombin time, PTT partial thromboplastin time, INR international normalization ratio, DIC disseminated intravascular coagulation, HIT heparin-induced thrombocytopenia, ITP immune thrombocytopenic purpura, TTP thrombotic thrombocytopenic purpura, H. pylori Helicobacter pylori, WBC white blood cell, HB hemoglobin, 2ry secondary, -ve negative, +ve positive)

Algorithmic approach for hematological manifestations of systemic lupus erythematosus (SLE). Classified by the affected component of the blood (platelets, HB, or WBC), in this approach, the authors suggest to broaden the differential diagnosis and to rule out non-rheumatological causes of mentioned abnormalities, including systemic diseases, infections, and drug-induced and primary hematological diseases. The evidence to support this approach is based on cumulative literature, current guidelines, and the author’s experience (Abbreviations: RA rheumatoid arthritis, R/O rule out, HCV hepatitis C virus, HIV human immunodeficiency virus, TSH thyroid stimulating hormone, PT prothrombin time, PTT partial thromboplastin time, INR international normalization ratio, DIC disseminated intravascular coagulation, HIT heparin-induced thrombocytopenia, ITP immune thrombocytopenic purpura, TTP thrombotic thrombocytopenic purpura, MAHA microangiopathic hemolytic anemia, H. pylori Helicobacter pylori, WBC white blood cell, HB hemoglobin, Plt platelets, 2ry secondary, -ve negative, +ve positive, BM bone marrow, MDS myelodysplastic syndrome)

¹Clinical description of SARS-CoV disease and approach to treatment:
Clinical judgment should be used to determine when symptoms trigger initiation of the algorithm in Figure B-2. The early symptoms of SARS-CoV disease usually include fever, chills, rigors, myalgia, and headache. In some patients, myalgia and headache may precede the onset of fever by 12–24 hours. Respiratory symptoms often do not appear until 2–7 days after the onset of illness and most often include shortness of breath and/or dry cough. Diarrhea, sore throat, and rhinorrhea may also be early symptoms of SARS-CoV disease. In the absence of fever, when screening patients for potential SARS-CoV disease, respiratory symptoms that would trigger the clinical algorithm are generally defined as lower respiratory tract symptoms (e.g., cough, shortness of breath, difficulty breathing). However, when screening patients who have a high risk of exposure to SARS-CoV (e.g., persons previously identified through contact tracing or self-identified as close contacts of a laboratory-confirmed case of SARS-CoV disease; persons who are epidemiologically linked to a laboratory-confirmed case of SARS-CoV disease), symptoms that should trigger the clinical algorithm should be expanded to include any of the following: sore throat, rhinorrhea, chills, rigors, myalgia, headache, diarrhea.
Although not diagnostic, the following laboratory abnormalities have been seen in some patients with laboratory-confirmed SARS-CoV disease: Lymphopenia with normal or low white blood cell countElevated hepatic transaminasesElevated creatine phosphokinaseElevated lactate dehydrogenaseElevated C-reactive proteinProlonged activated partial thromboplastin time
As of December 1, 2003, no specific treatment recommendations can be made for management of SARS-CoV disease. Empiric therapy for community-acquired pneumonia should include treatment for organisms associated with any community-acquired pneumonia of unclear etiology, including agents with activity against both typical and atypical respiratory pathogens. Treatment choices may be influenced by both the severity of and the circumstances surrounding the illness. Infectious disease consultation is recommended. The Infectious Diseases Society of America has guidelines for the management of community-acquired pneumonia at www.journals.uchicago.edu/IDSA/guidelines/.
²Exposure history for SARS-CoV, once SARS-CoV transmission is documented in the world:
In settings of no or limited local secondary transmission of SARS-CoV, patients are considered exposed to SARS-CoV if, within 10 days of symptom onset, the patient has: Close contact with someone suspected of having SARS-CoV disease, ORA history of foreign travel (or close contact with an ill person with a history of travel) to a location with documented or suspected SARS-CoV, ORExposure to a domestic location with documented or suspected SARS-CoV (including a laboratory that contains live SARS-CoV), or close contact with an ill person with such an exposure history.
In settings with more extensive transmission, all patients with fever or lower respiratory symptoms should be evaluated for possible SARS-CoV disease, since the ability to determine epidemiologic links will be lost.
For up-to-date information on where recent SARS-CoV transmission is suspected or documented, see the CDC and WHO websites: www.cdc.gov/sars and www.who.int.
³Clinical work-up: Clinicians should work up patients as clinically indicated. Depending on symptoms and exposure history, initial diagnostic testing for patients with suspected SARS-CoV disease may include: Complete blood count (CBC) with differentialChest radiographPulse oximetryBlood culturesSputum Gram’s stain and cultureTesting for viral respiratory pathogens, notably influenza A and B and respiratory syncytial virusLegionella and pneumococcal urinary antigen testing if radiographic evidence of pneumonia (adults only)
An acute serum sample and other available clinical specimens (respiratory, blood, and stool) should be saved for additional testing until a specific diagnosis is made.
SARS-CoV testing may be considered as part of the initial work-up if there is a high level of suspicion for SARS-CoV disease based on exposure history. For additional details on specialized laboratory testing options available through the health department and the Laboratory Response Network (LRN), see CDC’s SARS website: www.cdc.gov/sars/.
⁴Alternative diagnosis:
An alternative diagnosis should be based only on laboratory tests with high positive-predictive value (e.g., blood culture, viral culture, Legionella urinary antigen, pleural fluid culture, transthoracic aspirate). In some settings, PCR testing for bacterial and viral pathogens can also be used to help establish alternative diagnoses. The presence of an alternative diagnosis does not necessarily rule out co-infection with SARS-CoV.
⁵Radiographic testing:
Chest CT may show evidence of an infiltrate before a chest radiograph (CXR). Therefore, a chest CT should be considered in patients with a strong epidemiologic link to a known case of SARS-CoV disease and a negative CXR 6 days after onset of symptoms. Alternatively, the patient should remain in SARS isolation, and the CXR should be repeated on day 9 after symptom onset.
⁶Discontinuation of SARS isolation precautions:
SARS isolation precautions should be discontinued only after consultation with the local public health authorities and the evaluating clinician. Factors that might be considered include the strength of the epidemiologic exposure to SARS-CoV, nature of contact with others in the residential or work setting, strength of evidence for an alternative diagnosis, and evidence for clustering of pneumonia among close contacts. Isolation precautions should be discontinued on the basis of an alternative diagnosis only when the following criteria are met: Absence of strong epidemiologic link to known cases of SARS-CoV diseaseAlternative diagnosis confirmed using a test with a high positive-predictive valueClinical manifestations entirely explained by the alternative diagnosisNo evidence of clustering of pneumonia cases among close contacts (unless >1 case in the cluster is confirmed to have the same alternative diagnosis)All cases of presumed SARS-CoV disease identified in the surrounding community can be epidemiologically linked to known cases or locations in which transmission is known to have occurred.